0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xcorporeal
Its shares trade under the ticker XCRP. It has been listed since 29 February 2000. In the fiscal year to 31 December 2010, it reported revenue of $119 and a net loss of $4,236. At that date it held total assets of $28,000.
Xcorporeal, Inc. is a shell company which is engaged in the development of extracorporeal platform technology to be used in devices to replace the function of various human organs. The company is headquartered in Los Angeles, California. The company went IPO on 2000-02-29. The platforms lead to three initial products: portable artificial kidney (PAK), for attended care renal replacement therapy (RRT), for patients suffering from acute renal failure (ARF); a PAK for home hemodialysis for patients suffering from end stage renal disease (ESRD), and a wearable artificial kidney (WAK) for continuous ambulatory hemodialysis for treatment of ESRD.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 29 Feb 2000
- Employees
- 24
Leadership
Pay as last reported
- Dr. Kelly McCrannChairman of the Board, Chief Executive Officer, since 2007$97,411
- Mr. Lester SideropoulosGeneral Partner
- Mr. Robert WeinsteinChief Financial Officer, Secretary$297,092
- Dr. Victor GuraChief Medical and Scientific Officer, since 2006$1.3m
- Mr. Terren PeizerDirector, since 2006
- Dr. Hans-Dietrich PolascheggDirector
- Mr. Jay WolfDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xcorporeal Inc has several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team that possesses deep industry knowledge and expertise. This allows them to make informed decisions and drive the company towards its goals. Additionally, Xcorporeal Inc has developed innovative and patented technologies, giving them a competitive advantage over rivals. These technologies enable the company to deliver high-quality products that meet the evolving needs of customers.
Weaknesses
- Despite its strengths, Xcorporeal Inc also faces certain weaknesses that need to be addressed. One of the major weaknesses is the company's limited market presence and brand recognition compared to some of its competitors. This can hinder its ability to attract new customers and expand its customer base. Furthermore, Xcorporeal Inc may face challenges related to scaling up its production capacity to meet growing demand, which could affect its ability to fulfill orders in a timely manner.
Opportunities
- There are several opportunities available for Xcorporeal Inc to pursue. Firstly, the company can explore strategic partnerships with established medical device manufacturers to expand its distribution network and reach a wider customer base. This can help increase market penetration and revenue streams. Additionally, the growing demand for advanced medical technologies presents an opportunity for Xcorporeal Inc to capitalize on the market trend and further develop and enhance its product offerings. Moreover, the company can invest in research and development to innovate new products and technologies, driving its growth and increasing market share.
Threats
- Xcorporeal Inc must also be aware of potential threats that could impact its business. One of the significant threats is the intense competition within the medical device industry, characterized by the presence of well-established players and the emergence of new entrants. This can lead to price pressures and potentially erode Xcorporeal Inc's market share. Additionally, regulatory requirements and compliance with healthcare standards pose a threat to the company, as non-compliance can result in penalties and damage its reputation. Furthermore, changes in healthcare policies and reimbursement mechanisms can significantly affect the demand for Xcorporeal Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.